HB-0017

N/A

Report date: 2026/03/31 20:00:21

Base Information

Drug NameHB-0017
Drug Alias NameHB-0017HB0017
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin 17A inhibitors
TargetsInterleukin 17A
Therapy Area/IndicationsPlaque psoriasisPsoriasisSpondylitis, Ankylosing +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNew ZealandMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesHuaBo Biopharm Co LtdShanghai Huaota Biopharmaceutical Co LtdZhejiang Huahai Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHuaBo Biopharm Co LtdShanghai Huaota Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPsoriasisSpondylitis, Ankylosing +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A